Skip to main content
Equibles

Balyasny Asset Management L.P.

Position in SUPN — Supernus Pharmaceuticals, Inc.

CIK 1218710 Chicago, IL
Back to SUPN Full portfolio

Position in SUPN

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$3,988,511
+$3,640,224 QoQ
Shares Held
85,756
+1172.7% QoQ
Ownership
0.148%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#70
of 335 holders
Holding Since
Mar 2020
6 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SUPN Over Time

Shares Held

Position Value (USD)

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Jun 30, 2026

Balyasny Asset Management L.P. holds $126,095,704 across 18 Drug Manufacturers - Specialty & Generic names. SUPN ranks #9 (3.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LNTH
Lantheus Holdings, Inc.
 277,821 $30,821,461
2 KNSA
Kiniksa Pharmaceuticals International, plc
 309,682 $19,804,163
3 BIOA
BioAge Labs, Inc.
 702,858 $17,227,049
4 AMLX
Amylyx Pharmaceuticals, Inc.
 684,974 $12,302,133
5 TAK
Takeda Pharmaceutical Co Ltd
 511,336 $8,196,716
6 HIMS
Hims & Hers Health, Inc.
 218,958 $7,591,273
7 AMRX
Amneal Pharmaceuticals, Inc.
 434,132 $7,514,824
8 ALKS
Alkermes plc.
 142,366 $7,459,978

All Filings in SUPN

Export CSV
6 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $3,988,511 85,756
2026-03-31 $348,287 6,738
2022-06-30 $683,755 23,643
2022-03-31 $4,766,198 147,469
2020-06-30 $438,781 18,475
2020-03-31 $300,720 16,716